{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:56:54Z","timestamp":1782331014420,"version":"3.54.5"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,23]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The mechanisms of action of intravenous immunoglobulins (IVIg) in autoimmune diseases are not fully understood. The fixed duration of efficacy and noncumulative effects of IVIg in immune thrombocytopenia (ITP) and acquired von Willebrand disease (AVWD) suggest other mechanisms besides immunological ones. Additionally to the peripheral destruction of platelets in ITP, their medullary hypoproduction emerged as a new paradigm with rescue of thrombopoietin receptor agonists (TPO-RA). In an ITP mouse model, interleukin (IL)-11 blood levels increase following IVIg. IL-11 stimulates the production of platelets and other haemostasis factors; recombinant IL-11 (rIL-11) is thus used as a growth factor in post-chemotherapy thrombocytopenia. We therefore hypothesized that IVIg induces IL-11 over-production, which increases platelets, VWF and factor VIII (FVIII) levels in humans and mice. First, in an ITP mouse model, we show that IVIg or rIL-11 induces a rapid increase (72\u00a0h) in platelets, FVIII and VWF levels, whereas anti-IL-11 antibody greatly decreased this effect. Secondly, we quantify for the first time in patients with ITP, AVWD, inflammatory myopathies or Guillain\u2013Barr\u00e9 syndrome the dramatic IL-11 increase following IVIg, regardless of the disease. As observed in mice, platelets, VWF and FVIII levels increased following IVIg. The late evolution (4\u00a0weeks) of post-IVIg IL-11 levels overlapped with those of VWF and platelets. These data may explain thrombotic events following IVIg and open perspectives to monitor post-IVIg IL-11\/thrombopoietin ratios, and to assess rIL-11 use with or without TPO-RA as megakaryopoiesis co-stimulating factors to overcome the relative hypoproduction of platelets or VWF in corresponding autoimmune diseases, besides immunosuppressant.<\/jats:p>","DOI":"10.1111\/cei.13580","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T14:24:25Z","timestamp":1611930265000},"page":"258-266","source":"Crossref","is-referenced-by-count":8,"title":["IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans"],"prefix":"10.1093","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6206-9666","authenticated-orcid":false,"given":"A","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, Normandy University, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Repesse","sequence":"additional","affiliation":[{"name":"Laboratory of Haematology and Haemostasis, Normandy University, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ebbo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pital de la Timone, Assistance Publique des H\u00f4pitaux de Marseille, Aix Marseille University, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Allenbach","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Benveniste","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Vallat","sequence":"additional","affiliation":[{"name":"Centre de R\u00e9f\u00e9rence \u2018Neuropathies P\u00e9riph\u00e9riques Rares\u2019 et Service de Neurologie, H\u00f4pital Universitaire Limoges, Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Magy","sequence":"additional","affiliation":[{"name":"Centre de R\u00e9f\u00e9rence \u2018Neuropathies P\u00e9riph\u00e9riques Rares\u2019 et Service de Neurologie, H\u00f4pital Universitaire Limoges, Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Deshayes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, Normandy University, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Maign\u00e9","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, Normandy University, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"de Boysson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, Normandy University, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Karnam","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Centre de Recherche des Cordeliers, Sorbonne Universit\u00e9, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Delignat","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Centre de Recherche des Cordeliers, Sorbonne Universit\u00e9, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Lacroix-Desmazes","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Centre de Recherche des Cordeliers, Sorbonne Universit\u00e9, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Bayry","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Centre de Recherche des Cordeliers, Sorbonne Universit\u00e9, Universit\u00e9 de Paris, Paris, France"},{"name":"Indian Institute of Technology Palakkad, Palakkad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Aouba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, Normandy University, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"2022011417144140000_cei13580-bib-0001","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"Int Immunol"},{"key":"2022011417144140000_cei13580-bib-0002","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","article-title":"Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro","volume":"102","author":"Chang","year":"2003","journal-title":"Blood"},{"key":"2022011417144140000_cei13580-bib-0003","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2141.2009.07717.x","article-title":"Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and\/or decreased platelet production","volume":"146","author":"Nugent","year":"2009","journal-title":"Br J Haematol"},{"key":"2022011417144140000_cei13580-bib-0004","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/bjh.13444","article-title":"Intrinsically impaired platelet production in some patients with persistent or chronic immune thrombocytopenia","volume":"170","author":"Rivi\u00e8re","year":"2015","journal-title":"Br J Haematol"},{"key":"2022011417144140000_cei13580-bib-0005","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1111\/bjh.15890","article-title":"Autologous111 Indium-oxinate-labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor-agonists","volume":"186","author":"Mahevas","year":"2019","journal-title":"Br J Haematol"},{"key":"2022011417144140000_cei13580-bib-0006","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.hoc.2009.09.001","article-title":"Thrombopoietin and platelet production in chronic immune thrombocytopenia","volume":"23","author":"Kuter","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"2022011417144140000_cei13580-bib-0007","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841735","article-title":"Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia","volume":"10","author":"Al-Samkari","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"2022011417144140000_cei13580-bib-0008","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1182\/blood.V89.11.3897","article-title":"Interleukin-11: review of molecular, cell biology, and clinical use","volume":"89","author":"Du","year":"1997","journal-title":"Blood"},{"key":"2022011417144140000_cei13580-bib-0009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cytogfr.2016.06.002","article-title":"A panoramic review and in silico analysis of IL-11 structure and function","volume":"32","author":"Negahdaripour","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"2022011417144140000_cei13580-bib-0010","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/(SICI)1097-4652(199608)168:2<362::AID-JCP15>3.0.CO;2-5","article-title":"Murine interleukin-11 (IL-11) is expressed at high levels in the hippocampus and expression is developmentally regulated in the testis","volume":"168","author":"Du","year":"1996","journal-title":"J Cell Physiol"},{"key":"2022011417144140000_cei13580-bib-0011","doi-asserted-by":"crossref","first-page":"e101947","DOI":"10.1371\/journal.pone.0101947","article-title":"Optimal attenuation of experimental autoimmune encephalomyelitis by intravenous immunoglobulin requires an intact interleukin-11 receptor","volume":"9","author":"Figueiredo","year":"2014","journal-title":"PLOS ONE"},{"key":"2022011417144140000_cei13580-bib-0012","doi-asserted-by":"crossref","first-page":"30.1","DOI":"10.1002\/0471142735.im1530s113","article-title":"Mouse Models for Immune-Mediated Platelet Destruction or Immune Thrombocytopenia (ITP)","volume":"113","author":"Neschadim","year":"2016","journal-title":"Curr Protoc Immunol"},{"key":"2022011417144140000_cei13580-bib-0013","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/cei.13144","article-title":"GM-CSF and IL-4 are not involved in IVIG-mediated amelioration of ITP in mice: a role for IL-11 cannot be ruled out","volume":"193","author":"Lewis","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"2022011417144140000_cei13580-bib-0014","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1111\/trf.12680","article-title":"Cytokine profiles in mouse models of experimental immune thrombocytopenia reveal a lack of inflammation and differences in response to intravenous immunoglobulin depending on the mouse strain","volume":"54","author":"Leontyev","year":"2014","journal-title":"Transfusion (Paris)"},{"key":"2022011417144140000_cei13580-bib-0015","first-page":"4229","article-title":"IL-11 regulates autoimmune demyelination","volume":"183","author":"Gurfein","year":"2009","journal-title":"J Immunol Baltim Md 1950"},{"key":"2022011417144140000_cei13580-bib-0016","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1742-2094-9-134","article-title":"Evaluating the role of IL-11, a novel cytokine in the IL-6 family, in a mouse model of spinal cord injury","volume":"20","author":"Cho","year":"2012","journal-title":"J Neuroinflammation"},{"key":"2022011417144140000_cei13580-bib-0017","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood.V97.2.465","article-title":"Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models","volume":"97","author":"Denis","year":"2001","journal-title":"Blood"},{"key":"2022011417144140000_cei13580-bib-0018","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1365-2516.2008.01827.x","article-title":"A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease","volume":"14","author":"Ragni","year":"2008","journal-title":"Haemophilia"},{"key":"2022011417144140000_cei13580-bib-0019","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1160\/TH11-04-0274","article-title":"Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia","volume":"106","author":"Ragni","year":"2011","journal-title":"Thromb Haemost"},{"key":"2022011417144140000_cei13580-bib-0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1160\/TH12-06-0447","article-title":"Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A","volume":"109","author":"Ragni","year":"2013","journal-title":"Thromb Haemost"},{"key":"2022011417144140000_cei13580-bib-0021","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0955-3886(98)00025-3","article-title":"Therapeutic cytokine stimulation of thrombocytopoiesis","volume":"19","author":"Harker","year":"1998","journal-title":"Transfus Sci"},{"key":"2022011417144140000_cei13580-bib-0022","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1038\/emm.2017.217","article-title":"IL-11 promotes the treatment efficacy of hematopoietic stem cell transplant therapy in aplastic anemia model mice through a NF-\u03baB\/microRNA-204\/thrombopoietin regulatory axis","volume":"49","author":"Wang","year":"2017","journal-title":"Exp Mol Med"},{"key":"2022011417144140000_cei13580-bib-0023","first-page":"1668","article-title":"Interleukin-11 stimulates the proliferation of human hematopoietic CD34+ and CD34+CD33\u2013DR\u2013 cells and synergizes with stem cell factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor","volume":"21","author":"Lemoli","year":"1993","journal-title":"Exp Hematol"},{"key":"2022011417144140000_cei13580-bib-0024","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1537-2995.2009.02558.x","article-title":"Improved mouse models for the study of treatment modalities for immune-mediated platelet destruction","volume":"50","author":"Katsman","year":"2010","journal-title":"Transfusion"},{"key":"2022011417144140000_cei13580-bib-0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21307\/immunohematology-2020-006","article-title":"Serologic problems associated with administration of intravenous immune globulin (IVIg)","volume":"35","author":"Branch","year":"2019","journal-title":"Immunohematology"},{"key":"2022011417144140000_cei13580-bib-0026","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/stem.5530160724","article-title":"FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia","volume":"16","author":"Kaye","year":"1998","journal-title":"Stem Cells"},{"key":"2022011417144140000_cei13580-bib-0027","first-page":"713","article-title":"Therapeutic effect of interleukin-11 on thrombocytopenia in patients with hematologic malignancies after chemotherapy","volume":"32","author":"Zhang","year":"2010","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"2022011417144140000_cei13580-bib-0028","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/pbc.20980","article-title":"Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia","volume":"47","author":"Crow","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"2022011417144140000_cei13580-bib-0029","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"2022011417144140000_cei13580-bib-0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.transci.2016.12.017","article-title":"Mechanisms of action of intravenous immunoglobulin","volume":"56","author":"Chaigne","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"2022011417144140000_cei13580-bib-0031","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood.V81.4.901.901","article-title":"Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice","volume":"81","author":"Neben","year":"1993","journal-title":"Blood"},{"key":"2022011417144140000_cei13580-bib-0032","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.7150\/ijms.5638","article-title":"Designer cytokine hyper interleukin 11 (H11) is a megakaryopoietic factor","volume":"10","author":"Dams-Kozlowska","year":"2013","journal-title":"Int J Med Sci"},{"key":"2022011417144140000_cei13580-bib-0033","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/stem.5530130503","article-title":"Preclinical biology of interleukin 11: a multifunctional hematopoietic cytokine with potent thrombopoietic activity","volume":"13","author":"Goldman","year":"1995","journal-title":"Stem Cells"},{"key":"2022011417144140000_cei13580-bib-0034","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0140-6736(93)92000-J","article-title":"Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura","volume":"342","author":"Debr\u00e9","year":"1993","journal-title":"Lancet"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.13580","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.13580","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/204\/2\/258\/42195587\/cei13580.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/204\/2\/258\/42195587\/cei13580.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T23:34:46Z","timestamp":1670974486000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/204\/2\/258\/6403236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,22]]},"published-print":{"date-parts":[[2021,4,23]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13580","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5]]},"published":{"date-parts":[[2021,2,22]]}}}